Implementation of prices of Finished Medicines

3218. DR. (SHRIMATI) SAROJINI MAHISHI: Will ther Minister of HEALTH AND FAMILY WELFARE be pleased to state :

(a) whether it is a fact that the State Drug Authorities are looking after the implementation of prices of finished medicines fixed by Government;

(b) whether it is a fact that number of anti-TB and anti-Leprotic medicines are being sold at high prices n the market;

(c) whether the State Drug Authorities of Andhra Pradesh and Karnataka made any checking of the prices of these medicines;

(d) when was the checking done and what are the details thereof;

(e) what are the prices of major selling medicines of these diseases being charged from the consumers;

(f) whether these authorities found any overcharging of prices; and

(g) if so, the details thereof and action taken on each?

THE MINISTER OF TEXTILES AND THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI RAM NIWAS MIRDHA): (a) to (g) The information will be collec ted from the Department of Chemicals and Patrochemicals, Ministry of Industry and laid on the Table of the Sabha .

Marketing of Drugs for Treatment of Inflammation

3219. DR. (SHRIMATI) SAROJINI MAHISHI:
SHRI CHITTA BASU:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) the names of drugs allowed for marketing for treatment of inflammation in the country:

(b) whether any of these drugs have been found to be dangerous and toxic in any country of the world;

(c) whether there is any published report in the world about hazardous effect of any of these drugs;

(d) if so, the details thereof;

(e) whether Government have taken any steps to withdraw the marketing of any of these drugs ; and

(f) if so, the details thereof ?

THE MINISTER OF TEXTILES AND THE MINISTER OF HEALTH AND FAMILY WELFARE (SHRI RAM NIWAS MIRDHA): (a) to (f) The drugs licensed for marketing for treatment of Inflammatory disorders include Indomethacin, Phenylbutazone, Oxyphanbutazone, Ibuprofen, Naproxan, Piroxicam, Diclofenac Sodium, Flurbiprofen. Ketoprofen, Mefenemic acid and Auranofin. All these drugs have their charracteristic side effects.

While some ceuntries have preferred to withdraw Phenylbutazone, others have done so for Oxyehenbutazone on the benefit risk consideration Phanylbutazone and Oxyphenbutazone, like many other non-steroidal anti-inflammatory drugs are reported to cause adverse reactions to blood in vulnerable population.

Government have restricted the use of these two drugs for only ankylacing spondylitis and gouty arthri tis, which are musculo skeletal disorders and these drugs are prescribed for limited number of days to allay pain and inflammation associated with these disorders. Manufactures of these formulations have been asked to incorporate certain precautionary statements to safeguard against any indiscriminate use.